Navigation Links
Otonomy Completes $45.9 Million Series C Equity Financing
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it completed a Series C financing which raised $45.9 million in new funds. The investment was led by OrbiMed Advisors, LLC and new investors Aperture Venture Partners and Osage University Partners also participated. Existing investors Avalon Ventures, Domain Associates, Novo Ventures, RiverVest Venture Partners and TPG Biotech joined in the financing as well. Otonomy plans to use the financing to fund late-stage clinical trials for OTO-201 and OTO-104, development work to advance a third program to clinical trials and general corporate purposes.

(Logo: http://photos.prnewswire.com/prnh/20130806/MM59802LOGO)

The company also announced today that, in conjunction with the financing, Chau Q. Khuong has joined Otonomy's board of directors. Mr. Khuong is private equity partner at OrbiMed and brings significant experience in private company operations as well as business development.

"We are pleased to have some of the world's leading healthcare investors participate in this financing led by OrbiMed," said David A. Weber, Ph.D., president and CEO of Otonomy. "Following the successful completion of clinical trials for both of our product candidates, Otonomy is now positioned to complete late-stage trials for both OTO-104 and OTO-201, and further expand our product pipeline."

"Otic diseases remain underserved by the pharmaceutical industry and represent a significant unmet medical need with millions impacted each year in the U.S. alone," said Mr. Khuong. "OTO-104 and OTO-201 along with the company's proprietary technologies have established Otonomy as a leader in this field, and provide the opportunity for significant revenue generation and value creation."

About Otonomy

Otonomy is a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has two product candidates in clinical development. OTO-104 is a steroid that has completed a Phase 1b clinical trial in Meniere's disease patients. OTO-201 is an antibiotic that has recently completed a Phase 1b clinical trial in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. Otonomy is advancing both OTO-104 and OTO-201 into late-stage clinical trials. Additional product candidates are expected to target tinnitus and chronic forms of hearing loss. For more information please visit: www.otonomy.com.

About OrbiMed

OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector with approximately $7 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies on a worldwide basis, from venture capital start-ups to large multinational companies. OrbiMed's team includes over 60 experienced professionals with offices in New York, San Francisco, Shanghai, Mumbai and Herzliya. OrbiMed manages a series of private equity funds, public equity funds, royalty and debt funds, and other investment vehicles.

Contact:
Westwicke Partners
Stefan Loren, Ph.D.
Managing Director
443.213.0507
sloren@westwicke.com

Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com


'/>"/>
SOURCE Otonomy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
4. CryoLife Completes Acquisition of Hemosphere
5. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
6. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
7. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
8. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
9. Ablative Solutions Completes $5.3M Series A Financing
10. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
11. Spine Pain Management, Inc. Completes $500,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):